The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
Abstract
HomeCirculationVol. 141, No. 22Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBWill Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Courtney M. Campbell and Rami Kahwash Courtney M. CampbellCourtney M. Campbell Courtney M. Campbell, MD, PhD, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Suite 200, 473 W 12th Ave, Columbus, OH 43210. Email E-mail Address: [email protected] Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus. and Rami KahwashRami Kahwash Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus. Originally published9 Apr 2020https://doi.org/10.1161/CIRCULATIONAHA.120.047419Circulation. 2020;141:1739–1741Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: April 9, 2020: Ahead of Print SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel coronavirus responsible for the current pandemic, resulting in an escalating number of cases and fatalities worldwide. Despite a high infection rate of coronavirus disease 2019 (COVID-19), only an estimated 15% of patients require hospitalization, with 5% requiring intensive care. Nearly half (49%) of patients requiring intensive care died. How and why patients succumb to SARS-CoV-2 infection is not well understood. A poignant New York Times article described the sudden decompensation and death of a young physician after she had documented viral clearance and was preparing to go home.Several early publications from the Wuhan region of China focused on describing clinical characteristics of hospitalized patients with severe COVID-19 illness. These initial observational studies demonstrate in severe cases evidence of coagulation dysfunction through elevated D-dimer, elevated lactate dehydrogenase, elevated total bilirubin, and decreased platelets with slight or no changes in partial thromboplastin time or activated partial thromboplastin time. In patients with severe or fatal COVD-19, there is also evidence of end-organ damage with acute kidney injury and primarily mildly elevated troponin. In the study by Shi et al,1 a significantly higher percentage of patients with cardiac injury (average troponin I 0.19 µg/L) died compared with those patients without cardiac injury (51.2% versus 4.5%, respectively).The mechanism of cardiac injury for COVID-19 is uncertain. No series of cardiac imaging data, such as echocardiography or cardiac magnetic resonance imaging, has been published for patients with COVID-19. Theories include direct viral damage via the angiotensin-converting enzyme 2 receptor, myocarditis, systemic inflammatory response with cytokine storm, destabilized coronary plaques, and aggravated hypoxia. In case reports of COVID-19–related myocarditis, patients had minimal pulmonary involvement and significant cardiac involvement and recovered from COVID-19. Cardiac biomarkers in the myocarditis cases were much higher than the average values of cardiac injury in patients with COVID-19 reported in the observational studies. Whether myocarditis as a COVID-19 mechanism applies broadly is uncertain. Excessive cytokine release has also been observed in patients with COVID-19. High cytokines were also found in patients with SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus), but subsequent studies demonstrated that corticosteroids did not improve mortality and delayed viral clearance. Tocilizumab, an interleukin-6 inhibitor, is being studied as a potential treatment option. However, elevated cytokines in this context could be a biomarker of critical illness with COVID-19 rather than the pathogenic mediator.In a joint webinar between the Chinese Cardiology Association and the American College of Cardiology on March 28, 2020, the Chinese cardiologists described diffuse microvascular thrombi in multiple organs on autopsy review of COVID-19 nonsurvivors. Given this diffuse thrombosis, Chinese physicians recommended treatment of patients with COVID-19 with systemic anticoagulation, but no trials or publications have evaluated this approach. Similar findings of diffuse multiorgan microvascular thrombosis without viral infiltrates were seen in an autopsy case report for a patient who died of SARS.2Thrombotic microangiopathy (TMA) can occur in many different clinical scenarios, including pathogenic complement activation. The complement system is a mediator of the innate immune response that promotes inflammation, defends against bacterial infections, and often neutralizes infectious viruses. In b
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0950 · Cited by 4,349
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195
Severe Acute Respiratory Syndrome and Venous Thromboembolism in Multiple Organs
Yi, X., Wang, L., Aibin, L., Zhu, G., Ri-quan, L., Xu-you, Z., Wei-wei, R., & Ye-nan, W. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.182.3.436 · Cited by 86
Cited by
Menter, T., Haslbauer, J. D., Nienhold, R., Savic, S., Hopfer, H., Deigendesch, N., Frank, S., Turek, D., Willi, N., Pargger, H., et al. (2020) · Histopathology · doi:10.1111/his.14134 · Cited by 1,230
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
McFadyen, J. D., Stevens, H., & Peter, K. (2020) · Circulation Research · doi:10.1161/circresaha.120.317447 · Cited by 592
The pathophysiology of ‘happy’ hypoxemia in COVID-19
Dhont, S., Derom, E., Van Braeckel, E., Depuydt, P., & Lambrecht, B. N. (2020) · Respiratory Research · doi:10.1186/s12931-020-01462-5 · Cited by 544
Coagulopathy of Coronavirus Disease 2019
Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004458 · Cited by 534
Metadata
- Authors
- Campbell, C. M., & Kahwash, R.
- Venue
- Circulation
- Published
- 2020-06-02
- Volume
- 141
- Issue
- 22
- Pages
- 1739-1741
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3016046582
- Cited by
- 267
- References
- 4
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? https://app.cochat.ai/papers/10.1161/circulationaha.120.047419
- The paper
- Campbell, C. M., & Kahwash, R. (2020). Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis? Circulation. https://doi.org/10.1161/circulationaha.120.047419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.